Targeting Netrin-1 Mediates the Suppression of Osteolytic Bone Metastasis in Breast Cancer by Ugonin L

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Breast cancer bone metastasis is a major cause of morbidity with limited effective treatments.
• Current therapies for bone metastases have significant side effects and offer poor survival benefits.
• Ugonin L, a compound from Helminthostachys zeylanica, possesses anti-inflammatory properties, but its role in bone metastasis is unknown.

Purpose of the Study:

• To investigate the therapeutic potential of Ugonin L against breast cancer-associated osteolytic bone metastasis.
• To elucidate the molecular mechanisms underlying Ugonin L's effects on cancer cell behavior and bone remodeling.
• To evaluate the efficacy of Ugonin L in preclinical models of bone metastasis.

Main Methods:

• In vitro studies assessing Ugonin L's effects on breast cancer cell epithelial-mesenchymal transition (EMT), migration, and invasion.
• Identification of Netrin-1 (NTN-1) as a key mediator using molecular assays.
• Analysis of clinical data correlating NTN-1 expression with patient outcomes.
• In vivo experiments evaluating Ugonin L's impact on osteolytic bone lesions in mouse models.

Main Results:

• Ugonin L suppressed breast cancer cell EMT, migration, and invasion by inhibiting NTN-1 signaling via the Wnt/β-catenin pathway.
• Elevated NTN-1 expression correlated significantly with disease progression and poor survival in breast cancer patients.
• Ugonin L downregulated NTN-1, attenuated osteoclast differentiation, and suppressed osteolytic bone lesions in vivo.

Conclusions:

• Ugonin L effectively inhibits breast cancer cell motility and metastasis through NTN-1 and Wnt/β-catenin pathway suppression.
• Ugonin L demonstrates therapeutic potential by reducing osteoclastogenesis and preventing osteolytic bone destruction.
• Ugonin L represents a promising natural compound for preventing and treating osteolytic bone metastasis in breast cancer.